Category: Research
-
Harnessing AI to help diagnose brain tumours
With funding from The Brain Tumour Charity, researchers in Toronto, Canada are using the power of artificial intelligence (AI) to improve brain tumour diagnosis
-
Announcing our funding of a major new role at The University of Manchester
We’re delighted to announce our £1.35m investment in a pioneering drive to help accelerate research into brain tumours at one of the UK’s leading universities.
-
Reporting from the American Society of Clinical Oncology
Our Research Communications & Engagement Officer, Arshiya, shares some of the most exciting results from the American Society of Clinical Oncology (ASCO) conference
-
Predicting the risk of meningioma recurrence
Our funded research has created a tool to help clinicians predict meningioma recurrence
-
Announcing our research partnership investment with CRUK
Scottish scientist set to receive over £6 million from Cancer Research UK and The Brain Tumour Charity to find new ways to treat glioblastoma, one of the hardest types of cancer to treat.
-
Announcing our new £3.7m global research investment
Thanks to the support of our community, we’re pledging more than £3.7m to UK and international teams working towards our twin goals: doubling brain tumour survival and halving the harm caused by the disease
-
Tocagen’s ‘breakthrough’ gene therapy trial will continue
After undergoing an interim analysis, a phase 3 clinical trial called Toca 5 that tests a gene therapy in patients with recurrent brain cancer, will continue
-
Analysis shows Deputax-M is unsuccessful
Deputax-M failed to meet its target overall survival during an interim analysis of a phase 3 clinical trial in glioblastoma
-
Nivolumab fails to meet its target
Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT
-
Redefining medulloblastoma
New research from one of our funded grants gives much needed insight into group 3 and 4 medulloblastoma
-
5-ALA the ‘Pink Drink’ – What you need to know
There have been a number of headlines over the last two days about a ‘new treatment’ that may save thousands of lives for brain tumour patients
-
New treatments for diffuse midline gliomas
A new type of drug that targets a particular protein could become the first ever treatment designed for children with diffuse midline gliomas (formerly known as DIPG)
-
Pencil-beam scanning proton therapy could spare memory and cognitive function in children
Research presented recently at a conference in Milan showed that a particular type of radiation therapy could help spare children’s memory and thinking when they undergo treatment for brain tumours
-
Using artificial intelligence to assess the treatment response of brain tumours
A research team from Germany has used artificial intelligence to improve the assessment of treatment response in brain tumours
-
Innovating to defeat brain tumours
We’re thrilled to be the first ever UK charity to partner with the US-based Center for Advancing Innovation (CAI), an organisation dubbed ‘Tinder for start-ups’. We’ll be co-funding a pioneering initiative coordinated by the CAI, called The Brain Race. This will ask researchers and inventors from across the world to submit innovative ideas aimed at defeating brain tumours.
-
Unmet needs of patients and carers across the brain tumour pathway
A recent study highlights gaps in neuro-onoclogy services provided nationally
-
Further research needed to identify possible warning signs of a brain tumour
Further research needed to identify possible warning signs of a brain tumouriple subtle ‘changes’ and visit their GP at least once before being diagnosed with a brain tumour
-
Enzyme inhibitor shows promise for diffuse midline gliomas
New research shows that stopping the activity of the ACVR1 enzyme could slow tumour growth in diffuse midline gliomas (formerly known as DIPG)
-
Immunotherapy before surgery for recurring glioblastoma
Research suggests that treating people who have recurrent glioblastoma with immunotherapy before surgery, as well as afterwards, could be more effective
-
New ‘gel’ device lures aggressive brain tumour cells out
A new device nicknamed the “Tumor Monorail” has just received breakthrough device designation by the U.S. Food and Drug Administration (FDA)
-
Partners in crime: When patients become partners in research
Arshiya reports on an event she recently attended at Addenbrookes Hospital in Cambridge, held by Mr Mike Hart, a neurosurgery registrar.
-
Does your sex matter when you have a glioblastoma?
Recent research has shown that sex differences impact outcomes for people diagnosed with a glioblastoma. These differences go beyond hormone influences and were found to be intrinsic to tumour cells
-
Discovering how atypical teratoid rhabdoid tumours (ATRTs) are different
Research, funded by us as part of the INSTINCT programme, has found differences between aggressive atypical teratoid rhabdoid tumours (ATRTs) and other brain tumours.
-
Announcing our second Ask the Researcher event
Our successful Ask the Researcher event will give you the chance to hear more about how we’re moving closer to a cure